EGFR and non-small cell lung carcinoma: In addition, the median progression-free survival (PFS) of EGFR-mutant NSCLC patients is less than 2 years (Ramalingam et al., 2020) with first-line third-generation EGFR TKIs and disease progression eventually ensues.